Immuneering Corporation Class A Common Stock (IMRX) is a publicly traded Healthcare sector company. As of May 21, 2026, IMRX trades at $4.97 with a market cap of $315.08M and a P/E ratio of -3.91. IMRX moved +2.97% today. Year to date, IMRX is -24.05%; over the trailing twelve months it is +219.75%. Its 52-week range spans $1.10 to $10.08. Analyst consensus is strong buy with an average price target of $17.00. Rallies surfaces IMRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes IMRX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $4.97 |
| Market Cap | $315.08M |
| P/E Ratio | -3.91 |
| EPS | $-1.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.08 |
| 52-Week Low | $1.10 |
| Volume | 8.69K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-56.02M |
| Gross Margin | 0.00% |
5 analysts cover IMRX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.00.